Scientific Talks

Full talks, published as interactive web versions: scroll through them like a story, or switch to presentation mode (slides, speaker notes, full screen).

Webinar ObserveMHe · Calidad de vida y PROMs en dermatitis atópica · 26 de octubre de 2026

El papel de los PROMs en la toma de decisiones en dermatitis atópica

Lo que el paciente con dermatitis atópica nos cuenta, cómo lo leemos y qué hacemos con ello: la experiencia de la red NAVETA

Speaker · Webinar online (pieza grabada, ~10 min) · 12 slides · Galderma (patrocinio)

Ten minutes on what PROMs are for in atopic dermatitis when a decision is needed: disease burden, why AD needs PROMs and PREMs, four levels of decision, how to read a PROM (band, change and MCID), NAVETA in real-world practice, POEM, DLQI and itch by stage, controlled eczema versus quality of life, safety and experience as reported by the patient, and five decisions in the clinic.

NAVETADermatitis atópicaPROMs/PREMsPOEM / DLQIMCIDDecisión clínica

FarmaImpulso Baleares 2026 · 29 de octubre de 2026

NAVETA: la voz del paciente como motor de decisión clínica

Decisiones compartidas y valor de la farmacia hospitalaria · el modelo ZAFIRO

Speaker · INNSiDE Meliá, Palma · 27 slides · Johnson & Johnson (evento de educación médica)

Five years of NAVETA in 27 slides: from telepharmacy (2021) to shared decision-making, the ePROM/ePREM circuit, the ZAFIRO model (Pharmacy, Nursing and Gastroenterology), PROMaction, patient feedback and PROM-CARE 360 with AI. PDF version of the session, without videos or interactive slides; includes the best communication award at the 71st SEFH Congress.

NAVETAPROMs/PREMsZAFIROIA aplicadaFarmacia hospitalaria

Enfocando Juntos 2026 · 29 de octubre de 2026

Más allá de los datos clínicos

Lo que la OCT no ve: la voz del paciente con DMAE y EMD, la carga del tratamiento y el trabajo conjunto entre Farmacia Hospitalaria y Oftalmología

Speaker · Hotel Primus, Valencia (por videoconferencia) · 20 slides · Bayer

What the patient's voice adds to OCT in retina: AMD burden, the ePROM/ePREM circuit during intravitreal treatment, 330 patients in the retina programme, visual function and mental health by stage (NEI VFQ-25), discordance between visual acuity and PROMs, time in range, aflibercept 8 mg and fewer injections, coverage and barriers, and a proposal for a shared Pharmacy–Ophthalmology circuit. Includes a video demo of the voice avatar (VOCES project, in development) so low-vision patients can answer by speaking.

NAVETAOftalmologíaDMAE / EMDNEI VFQ-25Aflibercept 8 mgPROMs/PREMs

Curso «Miastenia gravis: de la unión neuromuscular al tratamiento dirigido» · 12 de noviembre de 2026 · 20:00–20:25

Farmacología de la miastenia gravis

Del síntoma a la diana: anti-FcRn, anti-C5 y anti-CD19 explicados para enfermería, farmacia hospitalaria y auxiliares de farmacia

Speaker · Hotel Mirador des Port, Maó · 25 slides · Colaboración UCB

From symptom to target in 25 slides (40 min), three animated videos and two interactive elements: a live QR poll at the start and a visual MG-ADL calculator. Designed for neurology, hospital pharmacy and pharmacy technicians, with acronyms spelled out on every slide. How it is treated today (Spanish consensus and ABN 2025 algorithm, two targets and a map of targeted therapies, including inebilizumab); anti-FcRn (rozanolixizumab); anti-C5 (zilucoplan); safety and practice (myasthenic crisis, drugs that worsen MG, access in the Spanish NHS, checklist, who does what and MG-ADL as a PROM).

Miastenia gravisRozanolixizumabZilucoplánAnti-FcRnInhibidores de C5Farmacia hospitalariaEnfermeríaMG-ADLAlgoritmo de tratamientoVídeo animadoInebilizumabVotación en directo

ADn Balear 2026 · 19 de noviembre de 2026

Lebrikizumab en práctica real

La voz del paciente en NAVETA · dermatitis atópica

Speaker · Espai Buit, Palma · 21 slides · Almirall

NAVETA lebrikizumab cohort in atopic dermatitis (39 patients, seven hospitals; data cut 18 Nov 2026), final 21-slide version for dermatology and hospital pharmacy: what NAVETA is and its year-by-year growth, cohort and patient profile (age, sex, treatment line and habits), standard PROM/PREM set, DLQI, POEM and itch at each follow-up point, naïve versus switch, itch at one year, domain-by-domain improvement, treatment satisfaction (TSQM), persistence (Kaplan-Meier curve), European real-world cohorts as context, PROMcare pathway and dashboard, real feedback returned to a patient, NAVETA Patient School and conclusions. PDF available.

NAVETADermatologíaDermatitis atópicaLebrikizumabPOEM / DLQI / NRSTSQMEscuela de Pacientes

Jornada presencial FARUPEIB · Esclerosis múltiple · 26 de noviembre de 2026 · 18:30–20:30

El valor de frenar

Evolución del tratamiento en esclerosis múltiple: el valor de frenar la progresión · presentación del moderador

Moderator · Hotel Palladium, Palma · 12 slides · FARUPEIB (colaboración Sanofi)

Moderator's thread for the meeting: programme and speakers, three decades of innovation in MS, why innovation is not only the drug, the multiple sclerosis cohort in NAVETA (183 patients, 6 centres, 4,238 questionnaires), from PROM to clinical decision, and from counting relapses to slowing progression; closes with the questions for the debate.

FARUPEIBEsclerosis múltipleNAVETATelefarmaciaValor en salud